Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Byung-Hyun | - |
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Jeon, Min Ji | - |
dc.contributor.author | Yu, Eun Sang | - |
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Choi, Hojoon | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Park, Yong | - |
dc.date.accessioned | 2021-08-31T14:40:41Z | - |
dc.date.available | 2021-08-31T14:40:41Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-01-08 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/58338 | - |
dc.description.abstract | Numerous studies have analysed the clinical efficacies of hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS). However, reports that compare the two HMAs, decitabine and azacitidine, in patients with lower-risk (low and intermediate-1) MDS are limited. We compared 5-day decitabine and 7-day azacitidine regimens in terms of treatment responses, survival outcomes, and adverse events in patients with lower-risk MDS with poor prognostic features. The overall response rates (ORRs) were 67.2% and 44.0% in the patients treated with decitabine and azacitidine, respectively (P = 0.014). While the median progression-free survival (PFS) was significantly better in the patients treated with decitabine than in those treated with azacitidine (P = 0.019), no significant differences in event-free and overall survival rates were observed between the two groups. Multivariate analysis revealed that compared with azacitidine treatment, decitabine treatment is significantly associated with a higher ORR (P = 0.026) and longer PFS (P = 0.037). No significant differences were observed in the incidence of grade 3 or higher haematologic adverse events in response to the two HMAs. In conclusion, in lower-risk MDS, especially with poor prognostic features, ORR and PFS were significantly better with 5-day decitabine treatment than with 7-day azacitidine treatment, with comparable safety. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | ACUTE MYELOID-LEUKEMIA | - |
dc.subject | LOW-DOSE DECITABINE | - |
dc.subject | PHASE-II | - |
dc.subject | SCORING SYSTEM | - |
dc.subject | OPEN-LABEL | - |
dc.subject | CANCER | - |
dc.subject | TP53 | - |
dc.subject | CARE | - |
dc.subject | MDS | - |
dc.title | Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dae Sik | - |
dc.contributor.affiliatedAuthor | Lee, Se Ryeon | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1038/s41598-019-56642-1 | - |
dc.identifier.scopusid | 2-s2.0-85077602559 | - |
dc.identifier.wosid | 000511420700004 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.10, no.1 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | LOW-DOSE DECITABINE | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | SCORING SYSTEM | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TP53 | - |
dc.subject.keywordPlus | CARE | - |
dc.subject.keywordPlus | MDS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.